The Lab Work Your Doctor Should Be Running (But Probably Isn't)
Afsoon, a PA-C who runs the Everyday Medicine channel, has built a following by pointing out the gaps between what standard medical care catches and what patients actually need monitored. This video targets a blind spot that affects a lot of GLP-1 users: the labs that get checked routinely are often not the ones that matter most for catching liver damage early.
The standard metabolic panel includes ALT and AST, two liver enzymes that most doctors glance at during annual bloodwork. If they're in range, the liver gets a passing grade and everyone moves on. The problem? ALT and AST can be normal in up to 50% of patients with MASH, especially in the early stages. By the time these enzymes rise significantly, there's often already meaningful liver inflammation or fibrosis happening under the surface.
Afsoon argues that GLP-1 users need a more complete picture. The video walks through several lab tests and markers that paint a better picture of liver health: GGT (gamma-glutamyl transferase), which is more sensitive to fatty liver changes than ALT alone; the FIB-4 index, which combines age, AST, ALT, and platelet count to estimate fibrosis risk; and direct markers of fibrosis like the ELF (Enhanced Liver Fibrosis) test. Most of these are inexpensive and can be calculated from routine blood work, but they're rarely ordered proactively.
Why GLP-1 Users Need Extra Attention
Here's the paradox: GLP-1 drugs are probably helping your liver. The data on semaglutide reducing liver fat and resolving steatohepatitis is strong. But that doesn't mean your liver doesn't need monitoring while you're on these medications. Rapid weight loss from any cause mobilizes fat from adipose tissue, and some of that fat passes through the liver on its way out. In rare cases, this can temporarily worsen liver inflammation even as the overall trajectory is improving.
The video also discusses the importance of monitoring liver function in the context of the medications that many GLP-1 users take concurrently. Statins, acetaminophen, and certain supplements can all affect the liver. When you add a GLP-1 drug that's changing metabolic dynamics and causing rapid weight loss, keeping tabs on liver function becomes more important, not less.
Afsoon makes a practical recommendation: get a baseline liver panel that includes GGT and calculate your FIB-4 score before starting a GLP-1 medication. Then recheck at 3 months, 6 months, and annually thereafter. If your FIB-4 is elevated at baseline, consider getting a FibroScan before starting treatment to establish a reference point for liver stiffness.
What the Video Gets Right
The emphasis on proactive monitoring is the best part of this video. The standard of care in many primary care offices is to check basic metabolic panels and call it done. Pointing out that this misses early liver disease in a huge percentage of patients is a genuinely useful public health message. The specific recommendations for FIB-4 and GGT are practical and evidence-based.
What Could Be Improved
The video title creates a bit of alarm that the content doesn't fully justify. The word "damage" implies that GLP-1 drugs are causing liver injury, when in reality the concern is more about catching pre-existing liver disease that standard labs miss. The video does explain this nuance, but the title framing could scare people away from beneficial medications.
There's also limited discussion of what to do if the labs come back abnormal. If your FIB-4 is elevated, what's the next step? Referral to hepatology? Imaging? Medication changes? Walking viewers through the decision tree after abnormal results would make the advice more actionable.
Questions to Ask at Your Next Blood Draw
Before your next lab appointment, request these additions to your standard panel:
Ask for GGT to be added. It costs very little and adds meaningful information about liver health that ALT and AST alone can miss. Ask your doctor or PA to calculate your FIB-4 index from the standard labs. It's a simple formula and can be done in seconds. If your FIB-4 is above 1.3, ask about further evaluation with imaging or referral.
Ask whether a FibroScan is available in your area. These non-invasive liver stiffness measurements take about 10 minutes and can detect fibrosis with reasonable accuracy. Ask how often your liver labs should be monitored given your specific situation. If you're on a GLP-1 drug plus a statin, the answer might be more frequently than standard annual bloodwork. Ask about hepatitis B and C screening if it hasn't been done. These viral infections can cause liver inflammation that compounds metabolic liver disease.
Understanding Why Standard Liver Tests Miss So Much
The reason standard liver enzyme tests are so unreliable for detecting MASH has to do with what these enzymes actually measure. ALT and AST are released from liver cells when they're damaged, so elevated levels indicate active cell death. But MASH doesn't always cause dramatic cell death. In many patients, the inflammation is chronic and low-grade, causing gradual cellular dysfunction without the acute injury that would spike enzyme levels. It's like the difference between a building slowly developing structural cracks versus suddenly collapsing. The slow damage is just as dangerous, maybe more so because it goes undetected, but it doesn't set off the same alarm bells.
The ALT-to-platelet ratio index (APRI) and FIB-4 are attempts to extract more information from standard blood work by combining multiple parameters. FIB-4 uses age, AST, ALT, and platelet count to estimate fibrosis probability. Platelets are included because the liver produces thrombopoietin, which stimulates platelet production. As the liver becomes fibrotic, thrombopoietin production decreases, and platelet counts drop. This is why a dropping platelet count in someone with metabolic risk factors should trigger a deeper liver evaluation, even if liver enzymes are normal. The FIB-4 score stratifies patients into low risk (below 1.3), intermediate risk (1.3-2.67), and high risk (above 2.67) for significant fibrosis. The intermediate and high-risk groups should be referred for imaging or biopsy.
The Role of Imaging in Liver Assessment
For patients whose blood-based markers suggest possible fibrosis, imaging provides the next level of assessment. Ultrasound can detect moderate-to-severe steatosis but is insensitive to mild fat accumulation and essentially useless for staging fibrosis. FibroScan (transient elastography) measures liver stiffness, which correlates with fibrosis stage. It's non-invasive, takes about 10 minutes, and provides a numerical score that can be tracked over time. MRI-based techniques, including MRI-PDFF (proton density fat fraction) for quantifying liver fat and MR elastography for assessing stiffness, offer the highest accuracy but are more expensive and less widely available.
For GLP-1 users specifically, having a baseline liver assessment before starting treatment creates a reference point that makes subsequent monitoring much more informative. If your FibroScan score is 8 kPa before starting semaglutide and drops to 6 kPa after a year of treatment, that's objective evidence that the medication is helping your liver. Without that baseline, you're flying blind and making assumptions about whether the treatment is working based on less reliable markers. Advocating for yourself to get this baseline assessment is one of the most valuable things you can do before starting GLP-1 therapy.
Medication Review: What Else Might Be Affecting Your Liver
Beyond monitoring, the video could have spent more time on medication interactions that affect liver health in GLP-1 users. Acetaminophen (Tylenol) is the most common over-the-counter medication that can damage the liver, and many patients take it regularly without considering the hepatic impact. Statins can cause liver enzyme elevation in some patients, though they're actually recommended for fatty liver because their anti-inflammatory effects benefit the liver. Certain supplements, particularly those marketed for liver health ironically, can contain ingredients that are hepatotoxic. Green tea extract in concentrated supplement form, for example, has been associated with liver injury, and kava and comfrey are well-documented hepatotoxins.
For patients on GLP-1 drugs, a medication and supplement review with their pharmacist or doctor can identify potential hepatotoxic exposures that might be counteracting the liver benefits of the GLP-1 therapy. This is especially important because patients seeking health optimization often take multiple supplements, and the cumulative liver burden of these products is rarely assessed.
The Timeline for Lab Monitoring on GLP-1 Drugs
For patients starting a GLP-1 medication, a practical monitoring schedule for liver health should include: baseline labs before starting treatment (complete metabolic panel with GGT, platelet count, and calculated FIB-4), repeat labs at 3 months (to catch early trends), again at 6 months, and then annually. If baseline FIB-4 is elevated, add a FibroScan before treatment and repeat at 12 months. If any labs trend in the wrong direction, don't wait for the next scheduled check. Earlier evaluation and possible imaging can catch problems before they become serious.
This monitoring schedule adds maybe two extra blood draws in the first year beyond what most patients already get for diabetes or weight management follow-up. The cost is minimal and the information gained is substantial. The alternative, finding out about advanced liver disease when it's too late for easy intervention, is both more expensive and more dangerous. Framing liver monitoring as a standard part of GLP-1 therapy rather than an optional add-on would serve patients much better and catch problems that the current standard of care routinely misses.
Who Should Watch This
Every GLP-1 user should watch this, full stop. But it's especially relevant for people who have been told they have a fatty liver and then weren't given any follow-up plan, which describes a disturbingly large number of patients. It's also useful for anyone with metabolic syndrome or type 2 diabetes, because the liver monitoring advice applies whether or not you're on a GLP-1 drug. Healthcare providers who primarily see patients in primary care will benefit from the reminder that standard liver enzyme panels have significant limitations for detecting early MASH.